Questcor Gets Hit Again

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Shares of Questcor (NASDAQ: QCOR ) closed down 7% today, after Blue Cross Blue Shield Michigan came out against Acthar Gel in all indications except for infantile spasm. In this video, Motley Fool health-care analyst David Williamson dives into today's news, and explains what it means for investors going forward.

Questcor is one of the most debated names in all of biotech. Its premium-priced drug, Acthar, is growing at a torrid pace -- and minting money in the process. However, recent events have created significant doubts about Questcor's future. Will insurance companies continue to cover the drug? Will a government investigation lead to huge fines? We highlight these high-profile issues inside our brand new premium research report on Questcor. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Report this Comment On December 27, 2012, at 5:42 PM, drdonrs wrote:

When are you people going to get the facts straight? BC/BS reiterated that Acthar Gel is not indicated for steroid responsive immune disorders, only for non responsive to steroid disorders such as MS. All indications will usually require pre-authorization as any upper tier drug presently does. So instead of feeding into the short frenzy why not get your facts in place. A recent article by Fools indicated that the company produces nutritional supplements...does anyone read thefacts or is everyone just a big Fool?
Report this Comment On December 27, 2012, at 7:45 PM, JiminyBillyBob wrote:

I agree with drdonrs. My assessment is on the QCOR public board:
http://boards.fool.com/blue-cross-blue-shield-michigan-30453...

updated 10 hours ago Sponsored by:
	DOW	15,307.17	-80.41	-0.52%
	S&P 500	1,655.35	-13.81	-0.83%
	NASD	3,463.30	-38.82	-1.11%

UNH	$62.28		-0.59	-0.94%
UnitedHealth Group		CAPS Rating:

QCOR	$36.01		-1.20	-3.22%
Questcor Pharmaceu…		CAPS Rating:

AET	$59.53		-0.74	-1.23%
Aetna, Inc.		CAPS Rating:

My Watchlist

3

Questcor Gets Hit Again

Watch stocks you care about

Comments from our Foolish Readers

Report this Comment On December 27, 2012, at 5:42 PM, drdonrs wrote:

Report this Comment On December 27, 2012, at 7:45 PM, JiminyBillyBob wrote:

Add your comment.

Compare Brokers

Report This Comment

Sending report...

Today's Market

Create My Watchlist

You don't seem to be following any stocks yet!

Related Tickers